Receptors coupled to heterotrimeric GTP-binding proteins (G-proteins) are integral membrane proteins involved in the transmission of signals from the extracellular environment to the cytoplasm. A variety of external stimuli, including neurotransmitter, hormones, and phospholipids, can activate the G-protein coupled receptors (GPCRs). Therefore, the G-protein coupled receptors and signal transduction pathways represent important speci®c targets for a variety of therapeutic approaches, ranging from the control of blood pressure, allergic response, kidney function and hormonal disorders, to neurological diseases and chronic pain (Edwards et al., 2000) . GPCRs share the common structural feature of a single polypeptide with seven membrane-spanning domains (Wess, 1997) . Binding of speci®c agonists (ligands) to the receptors leads to the subsequent activation of heterotrimeric G-proteins (binding of GTP) and G-protein coupled signaling pathways. The heterotrimeric G-proteins are composed of a, b and g subunits. The Ga proteins comprise four subfamilies, the G s , G i/o , G q , and G 12/13 . Each of these groups functions to activate dierent subsets of eectors: the G s and the G i/o regulate intracellular cAMP concentration by activating and inhibiting adenylyl cyclases, respectively; and the G q subfamily mediates the function of phospholipase C-b (Simon et al., 1991) , a family of key enzymes essential for the regulation and generation of intracellular second messengers (PIP 2 , IP 3 , and Ca
2+
) (Rhee and Choi, 1992) . The Ga 12/13 subfamily has been implicated in a number of cellular functions, including Rho-dependent cytoskeletal shape changes, activation of c-Jun Nterminal kinase, and stimulation of Na + /H + exchange (Dhanasekaran and Dermott, 1996; Lin et al., 1996; Collins et al., 1997; Voyno-Yasenetskaya et al., 1996; Gohla et al., 1999) . In addition, there is substantial evidence that Ga 12/13 proteins mediate signaling pathways involved in cell growth and tumorigenesis (Chan et al., 1993; Jiang et al., 1993; Jones and Gutkind, 1998; Dermott et al., 1999) . Whereas Ga 12 proteins have been directly linked to regulatory molecules such as the Rho-directed guanine nucleotide exchange factor p115 Hart et al., 1998) and the GTPase-activating protein RasGAP1 , the signi®cance of these interactions in relation to the developmental and oncogenic roles of Ga 12 proteins has not been clearly de®ned.
In this study, we identi®ed a putative G-protein coupled receptor that interacts with Ga 12 in yeast twohybrid assays. Northern blot analysis indicates that the expression of the receptor is highly restricted to the prostate tissues. Little or no expression was detected in other tissues. Furthermore, the prostate-speci®c Gprotein receptor was greatly elevated in human prostate cancers compared to normal prostate tissues. Together, these results suggest that the prostate-speci®c G-protein coupled receptor (PSGR) may couple to Ga 12 -mediated signaling pathway and participate in the regulation of prostate cell growth and proliferation.
To understand the potential function of Ga 12 protein in prostate cancer cells, we screened a human prostate MatchMaker cDNA library using Ga 12 as bait. A number of positive colonies have been obtained in the yeast two-hybrid screening. One of the clones identi®ed encodes a putative G-protein coupled receptor. Since the clone did not contain the complete protein sequence, the 5' end of the protein was isolated by 5' RACE ± PCR. The compiled full-length cDNA contains an open reading frame of 320 amino acids with seven putative transmembrane domains (TMI to TMVII) (Figure 1 ). Chromosomal mapping assigned PSGR to chromosome 11p15, one of the regions that are clustered with G-protein coupled receptors. Sequence analysis indicates that the new PSGR protein shares about 30% sequence identity with various Gprotein coupled odorant receptor proteins and a gustatory-speci®c G protein-coupled receptor (Abe et al., 1993) .
To con®rm the interaction of Ga 12 and the receptor, yeast cells were cotransformed with Ga 12 and a large fragment of PSGR receptor (amino acids 120 ± 320) in the DNA-binding domain and the activation domain vectors, respectively. The transformed yeast cells were cultured on the selection plate (-Trp/-Leu/-His) to examine the interaction of the two proteins. As shown in Figure Matched normal/tumor samples were obtained from dierent human tissues, including kidney, breast, prostate, uterus, ovary, cervix, colon, lung, stomach, rectum, small intestine and dierent cancer cell lines (P) (HeLa, Daudi, K562, HL60, G361, A549, Molt-4, SW480, and Raji). (c) The membrane was blotted using 32 P-labeled Ubiquitin as a probe, demonstrating equal amount of cDNAs between the normal/tumor (N/T) samples were loaded to the membrane. (d) PSGR is only expressed in the prostate and is overexpressed in prostate cancer samples. The membrane was blotted using a speci®c PSGR probe. Three matched pairs of prostate normal tissues and adenocarcinoma tumor tissues were isolated from a 65-year-old (1), a 67-yearold (2), and a 68-year-old (3) Caucasian patient, respectively (arrow). Overexpression of PSGR was observed in two of the three pairs of prostate tumors tissues (N for normal prostate tissues; T for prostate tumor tissues)
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The prostate-specific G-protein coupled receptor C Xia et al Northern blot analysis. As shown in Figure 3 , the expression of PSGR is exclusively restricted to human prostate tissues. Little or no signal was detected in other tissues (Figure 3 ). Expression analysis with dierent human tumor tissues further con®rmed that the expression of PSGR is exclusively restricted to human prostate tissues (Figure 4) . Therefore, PSGR is a prostate-speci®c G-protein coupled receptor.
To examine the potential role of PSGR in prostate cancer progression and development, we further examined the expression of the receptor in prostate tumors using PCR and Southern blot analysis with Matched Tumor/Normal prostate tissues from individual patients (Clontech Laboratories, CA, USA). As shown in Figure 4a , the expression level of the prostate-speci®c receptor is increased signi®cantly in human prostate tumors as compared to that in normal prostate tissues using matched cDNA pairs from tumor and normal tissues in our PCR assays. Southern blot analysis on cDNA pairs derived from dierent tumor and corresponding normal tissues of individual patients further demonstrated that PSGR only expressed in human prostate tumor and normal tissues, not in other tumors or normal tissues (Figure 4b ± d ). The expression level of PSGR was dramatically increased in two of the three pairs of human prostate cancer samples (Figure 4d, bottom) , suggesting a potential role of the receptor in human prostate tumor progression and development. Together, these experiments demonstrate that this new receptor is a prostate-speci®c G-protein coupled receptor (PSGR) with tumor speci®c overexpression in prostate cancer samples.
During the preparation of this study for publication, a paper describing the prostate-speci®c G-protein coupled receptor (PSGR) was independent reported by another group (Xu et al., 2000) . This study con®rms our ®nding that PSGR is primarily expressed in prostate tissues and in the epithelial cells of the prostate gland. Furthermore, the expression of PSGR was dramatically increased in more than 60% of the prostate tumors, consistent with our ®nding that the receptor protein is overexpressed in prostate cancers.
Besides the traditional G-protein coupled signaling pathways, G-protein coupled receptors have also been shown to participate in the MAP kinase signaling pathways and the Rho/Cdc42/Rac-PAK signaling pathways in dierent cells and tissues (Lopez-Ilasaca et al., 1997; Gutkind, 1998a; Marinissen et al., 1999; Whitehead et al., 2001) , suggesting a direct role of Gprotein coupled receptors in cell growth and proliferation processes. A number of studies demonstrated that many GPCRs and their signaling pathways have oncogenic potential and can induce tumor formation. For example, the mas oncogene, a putative GPCR, can induce the formation of tumors in mice (Young et al., 1986) . Other G-protein coupled receptors, such as serotonin 1C, muscarinic m1, m3, and m5, and adrenergic a1 receptors, have been demonstrated to transform contact-inhibited cultures of rodent ®bro-blasts when persistently activated (Julius et al., 1989; Gutkind et al., 1991; Allen et al., 1991) , suggesting that G-protein coupled receptors can behave as agonistdependent oncogenes.
Studies on constitutive activation mutants of Gprotein coupled receptors and G-proteins in cancers and other disease states further demonstrated that GPCRs and G-proteins play an important role in both normal and aberrant growth control (Crespo et al., 1994; Radhika and Dhanasekaran, 2001; Gutkind, 1998b) . Constitutive activation mutations of GPCRs have been implicated in a number of human neoplasias, including thyroid adenomas, small cell lung carcinoma, colon adenomas and carcinomas, and gastric hyperplasia and cancers (see review, Gutkind, 1998b) . Furthermore, constitutively active mutants of G-protein alpha subunits have been found as transforming oncogenes, such as the Gas as the gsp oncogene, Gai as the gip2 oncogene, and Ga 12 as the gep oncogene (Landis et al., 1989; Lyons et al., 1990; Xu et al., 1993 Xu et al., , 1994 Chan et al., 1993) . Therefore, active G-protein coupled receptors and active Gprotein mutants have been found in a number of human tumors and are potentially involved in the proliferation pathways of the cells (Dhanasekaran et al., 1995; Radhika and Dhanasekaran, 2001) . We are in the process of generating and testing the potential role of the constitutively-active PSGR receptor and its overexpression in prostate cancer.
In summary, we have identi®ed a putative G-protein coupled receptor that interacts with Ga 12 in yeast-two hybrid assays. The receptor is expressed exclusively in human prostate tissues. Furthermore, overexpression of the prostate-speci®c receptor in prostate cancers suggests this tissue-speci®c GPCR and its signaling pathway(s) may play an important role in human prostate tumor development.
